Lung Cancer Diagnostic and Screening Market Report 2026

The lung cancer diagnostic and screening market size has grown strongly in recent years. It will grow from $2.56 billion in 2025 to $2.8 billion in 2026 at a compound annual growth rate (CAGR) of 9.4%. The growth in the historic period can be attributed to high prevalence of smoking-related lung cancer, widespread use of chest x-ray and ct imaging, increasing hospital-based diagnostic infrastructure, rising awareness of early lung cancer detection, growth of biopsy-based diagnostic confirmation.

The lung cancer diagnostic and screening market size is expected to see strong growth in the next few years. It will grow to $4.04 billion in 2030 at a compound annual growth rate (CAGR) of 9.6%. The growth in the forecast period can be attributed to expansion of national lung cancer screening initiatives, increasing adoption of low-dose ct screening, growing demand for biomarker and blood-based tests, rising healthcare investments in oncology diagnostics, improved access to diagnostic imaging centers. Major trends in the forecast period include rising adoption of early lung cancer screening programs, growing use of advanced imaging and biomarker tests, increasing focus on high-risk population screening, expansion of non-invasive diagnostic techniques, rising integration of multimodal diagnostic pathways.

The growing incidence of lung cancer is anticipated to drive the expansion of the lung cancer diagnostic and screening market in the coming years. Lung cancer is a malignant condition characterized by symptoms such as persistent coughing, chest pain, and shortness of breath, and results from the uncontrolled growth of abnormal cells within lung tissue. Lung cancer diagnosis and screening support early detection of the disease through various tests, including incisional biopsy and bronchoscopy. For example, in January 2023, according to the American Cancer Society, a U.S.-based government organization, the United States recorded around 238,340 new lung cancer cases, comprising 117,550 cases in men and 120,790 cases in women. In addition, there were approximately 127,070 lung cancer-related deaths, including 67,160 among men and 59,910 among women. Consequently, the rising prevalence of lung cancer is contributing to the growth of the lung cancer diagnostic and screening market.

Major players in the lung cancer diagnostics and screening market are concentrating on the development of blood-based tests that incorporate machine learning technologies, including whole-genome machine learning, to enable more accessible and convenient lung cancer screening and strengthen their competitive position. Whole-genome machine learning involves the use of machine learning algorithms to examine and interpret extensive genetic data, covering the complete genome of an organism. For example, in October 2023, DELFI Diagnostics Inc., a US-based company specializing in accessible blood-based testing, introduced FirstLook Lung, a blood test that applies whole-genome machine learning to analyze cell-free DNA fragments, thereby improving lung cancer screening with a 99.7% negative predictive value (NPV). The test, intended for use as part of routine blood testing, helps identify individuals who may have lung cancer, including those in early stages. By addressing the low adoption of LDCT screening, the test seeks to enhance overall population health outcomes.

In May 2025, Johnson & Johnson MedTech, the medical technology arm of Johnson & Johnson Private Limited, entered into a partnership with Qure.ai, an India-based artificial intelligence healthcare company, to support the early identification of lung cancer in India using AI-enabled screening solutions. Through this collaboration, Johnson & Johnson MedTech and Qure.ai plan to implement Qure.ai’s AI-powered imaging technologies across a network of hospitals, facilitating earlier detection of lung cancer nodules and enhancing the likelihood of timely treatment and improved patient outcomes. Qure.ai is an India-based company focused on developing artificial-intelligence-based diagnostic solutions for radiology and medical imaging.

Major companies operating in the lung cancer diagnostic and screening market are Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Danaher Corporation, Siemens Healthcare GmbH, FUJIFILM Corporation, Koninklijke Philips N.V., GE Healthcare Bio Sciences AB, Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., Qiagen Inc., Myriad Genetic Laboratories Inc., NeoGenomics Laboratories Inc., Canon Medical Systems Corporation, Oncimmune Holdings Plc, Riverain Technologies LLC, VisionGate, Foundation Medicine Inc., Biodesix, OncoCyte, Broncus Medical Inc.

North America was the largest region in the lung cancer diagnostic and screening market in 2025. The regions covered in the lung cancer diagnostic and screening market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the lung cancer diagnostic and screening market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the lung cancer diagnostic and screening market by increasing costs associated with imported imaging equipment, biopsy devices, reagents, and diagnostic consumables. These effects are more pronounced for advanced imaging systems and biomarker testing kits, particularly in asia-pacific and europe where diagnostic supply chains are globally integrated. Hospitals and diagnostic imaging centers face higher procurement and maintenance costs. However, tariffs have encouraged local manufacturing of consumables, regional sourcing of diagnostic tools, and investments in domestic diagnostic capabilities, supporting long-term market resilience.

The lung cancer diagnostic and screening market research report is one of a series of new reports that provides lung cancer diagnostic and screening market statistics, including lung cancer diagnostic and screening industry global market size, regional shares, competitors with a lung cancer diagnostic and screening market share, detailed lung cancer diagnostic and screening market segments, market trends and opportunities, and any further data you may need to thrive in the lung cancer diagnostic and screening industry. This lung cancer diagnostic and screening market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Lung cancer diagnosis and screening involves the use of examinations and diagnostic techniques to detect and confirm lung cancer, with the aim of enabling early identification and accurate diagnosis to support effective treatment planning. It is widely applied in the detection and management of squamous cell carcinoma, adenocarcinoma, and large cell carcinoma.

The primary products used in lung cancer diagnostics and screening include instruments, consumables, and accessories. Instruments are devices designed to analyze or interpret diagnostic results and to process samples required for diagnostic procedures. The different types of tests include biomarker tests, imaging tests, biopsies, blood tests, and others, which are used to diagnose various cancer types such as non-small cell lung cancer and small cell lung cancer. These diagnostic solutions are utilized by a range of end users, including hospitals, independent diagnostic laboratories, diagnostic imaging centers, cancer research institutes, and others.

The lung cancer diagnosis and screening market consists of revenues earned by entities by providing positron emission tomography (PET) scanners, and bronchoscopy. The market value includes the value of related goods sold by the service provider or included within the service offering. The lung cancer diagnosis and screening market also includes sales of products such as liquid biopsy kits, molecular testing kits, and biopsy tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.